Anjali Gulati, MD
Cardiovascular Disease (Cardiology) · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 26
- 6 carriers
- Office
- 1
Offices
1 location
Hospitals listed: El Camino Health · Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
26 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Gulati’s office at (408) 358-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
26 of 26 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A62620 · Current
Licensed to practise in California · since 1997 · expires 2028-08-31 · Bhopal University, Gandhi Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$294,848
Medicare paid this office $294,848 for 439 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 63 | $89,678 | $1,423 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 63 | $46,766 | $371 |
| Return visit (30+ min) | 140 | $28,204 | $103 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 132 | $24,532 | $179 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 80 | $23,231 | $95 |
See all 24 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 63 | $89,678 | $1,423 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 63 | $46,766 | $371 |
| Return visit (30+ min) | 140 | $28,204 | $103 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 132 | $24,532 | $179 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 80 | $23,231 | $95 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 13 | $9,979 | $768 |
| Critical care, first 30-74 minutes | 23 | $9,925 | $165 |
| New patient visit (60+ min) | 38 | $6,957 | $183 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 108 | $5,960 | $53 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $5,699 | $130 |
| Long return visit (40+ min) | 33 | $5,596 | $147 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 66 | $4,393 | $67 |
| Short return visit (20+ min) | 31 | $4,102 | $76 |
| Emergency department visit with high level of medical decision making | 33 | $3,843 | $116 |
| Injection of drug or substance into vein | 66 | $2,296 | $35 |
| Short return visit | 35 | $1,987 | $48 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 91 | $1,326 | $12 |
| Injection, regadenoson, 0.1 mg | 64 | $1,190 | None |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,029 | $86 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 16 | $976 | $61 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 120 | $962 | $7 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 14 | $268 | $19 |
| Infusion, normal saline solution, 250 cc | 65 | $261 | None |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 12 | $191 | $10 |
Who their Medicare patients are
439 Original Medicare patients in 2024. Average age 79 · Under 65 3% · 85 and older 25% · Women 56% · Also on Medicaid 21% · Health risk score 1.91. Above the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Diabetes 46% · Coronary heart disease 45% · Atrial fibrillation 41% · Heart failure 37% · Chronic kidney disease 35% · Cancer 23% · Depression 23% · Stroke 21% · COPD 20% · Dementia 19%.
The office billed $870,248, Medicare allowed $387,204 and paid $294,848; for 2,670 services of 50 kinds; $1,493 of it was for drugs given in the office and $293,354 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 439 | 2,670 | 79 | 1.91 | $870,248 | $294,848 |
| 2023 | 535 | 4,576 | 79 | 1.57 | $885,207 | $336,741 |
| 2022 | 586 | 4,809 | 79 | 1.60 | $803,082 | $309,692 |
| 2021 | 563 | 5,792 | 78 | 1.64 | $887,218 | $338,912 |
| 2020 | 596 | 2,556 | 78 | 1.77 | $653,263 | $227,676 |
| 2019 | 653 | 2,377 | 77 | 1.70 | $575,579 | $222,571 |
| 2018 | 586 | 2,024 | 78 | 1.57 | $503,513 | $178,349 |
| 2017 | 542 | 1,631 | 78 | 1.60 | $388,470 | $140,180 |
| 2016 | 451 | 3,164 | 77 | 1.55 | $445,205 | $154,258 |
| 2015 | 412 | 4,535 | 76 | 1.40 | $654,650 | $215,808 |
| 2014 | 260 | 3,510 | 76 | 1.42 | $395,386 | $134,703 |
| 2013 | 264 | 1,166 | 76 | 1.36 | $354,701 | $111,461 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 26 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 57 | $87,880 | $1,542 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 57 | $46,496 | $408 |
| Return visit (30+ min) | 153 | $32,223 | $108 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 121 | $24,394 | $192 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 73 | $24,280 | $105 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 18 | $16,845 | $936 |
| Critical care, first 30-74 minutes | 22 | $14,848 | $188 |
| New patient visit (60+ min) | 47 | $9,326 | $198 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 58 | $9,318 | $150 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 123 | $8,082 | $59 |
| Short return visit (20+ min) | 38 | $5,043 | $83 |
| Long return visit (40+ min) | 27 | $4,545 | $157 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 56 | $3,996 | $71 |
| Short return visit | 58 | $3,609 | $55 |
| Emergency department visit with high level of medical decision making | 18 | $2,959 | $148 |
| Injection of drug or substance into vein | 57 | $2,253 | $40 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 201 | $1,715 | $7 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 19 | $1,448 | $72 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,148 | $96 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 72 | $1,068 | $14 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 50 | $895 | None |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 18 | $415 | $23 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 12 | $247 | $11 |
| Infusion, normal saline solution, 250 cc | 57 | $228 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 11 | $192 | $17 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 11 | $126 | $11 |
2022: 21 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 56 | $88,724 | $1,557 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 60 | $50,125 | $411 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 112 | $25,295 | $207 |
| Return visit (30+ min) | 127 | $21,701 | $114 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 18 | $18,583 | $978 |
| Critical care, first 30-74 minutes | 20 | $16,015 | $188 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $13,212 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $8,799 | $173 |
| New patient visit (60+ min) | 44 | $8,035 | $183 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 105 | $6,965 | $62 |
| Long return visit (40+ min) | 42 | $6,720 | $156 |
| Short return visit | 101 | $6,390 | $49 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 59 | $4,308 | $72 |
| Injection of drug or substance into vein | 59 | $2,515 | $42 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 261 | $2,059 | $7 |
| Short return visit (20+ min) | 17 | $1,677 | $76 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 115 | $1,561 | $13 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 59 | $925 | None |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 11 | $813 | $74 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 16 | $376 | $22 |
| Infusion, normal saline solution, 250 cc | 60 | $252 | None |
2021: 26 services
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 61 | $99,959 | $1,612 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 61 | $51,658 | $417 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 124 | $26,027 | $203 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 72 | $20,037 | $94 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 25 | $19,690 | $788 |
| Return visit (30+ min) | 114 | $16,765 | $110 |
| Critical care, first 30-74 minutes | 19 | $13,446 | $195 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 21 | $10,966 | $522 |
| New patient visit (60+ min) | 53 | $10,633 | $201 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 149 | $10,050 | $63 |
| Short return visit | 136 | $9,599 | $52 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 51 | $9,415 | $162 |
| Long return visit (40+ min) | 45 | $7,911 | $165 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 83 | $5,495 | $65 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 16 | $3,717 | $232 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 20 | $3,439 | $86 |
| Injection of drug or substance into vein | 53 | $2,394 | $44 |
| Emergency department visit with high level of medical decision making | 12 | $1,876 | $156 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 25 | $1,855 | $74 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 110 | $1,798 | $14 |
| Short return visit (20+ min) | 20 | $1,793 | $81 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 76 | $1,460 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 174 | $1,442 | $7 |
| Programming of dual lead pacemaker system | 12 | $1,005 | $67 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 24 | $545 | $23 |
| Infusion, normal saline solution, 250 cc | 80 | $280 | None |
2020: 28 services
| Return visit (30+ min) | 188 | $27,668 | $95 |
| Critical care, first 30-74 minutes | 40 | $23,974 | $201 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 106 | $23,057 | $213 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 88 | $17,336 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $15,815 | $96 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 26 | $13,558 | $521 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 17 | $13,360 | $786 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 180 | $13,073 | $67 |
| Long return visit (40+ min) | 81 | $11,364 | $125 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 31 | $7,647 | $247 |
| New patient visit (60+ min) | 42 | $7,589 | $181 |
| Short return visit | 104 | $5,972 | $45 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 44 | $5,861 | $64 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 26 | $5,138 | $99 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 36 | $3,026 | $84 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 11 | $2,940 | $267 |
| Short return visit (20+ min) | 34 | $2,469 | $65 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 128 | $2,442 | $16 |
| Injection, regadenoson, 0.1 mg | 11 | $2,083 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 25 | $1,587 | $63 |
| Ultrasound of heart with probe in esophagus, with report | 15 | $1,546 | $103 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 128 | $1,088 | $8 |
| Anticoagulant management of patient taking warfarin | 11 | $635 | $11 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 12 | $298 | $25 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 18 | $285 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 13 | $250 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 16 | $210 | $13 |
| Infusion, normal saline solution, 250 cc | 27 | $14 | None |
2019: 22 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 181 | $39,098 | $207 |
| Long return visit (40+ min) | 160 | $28,907 | $127 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 124 | $24,618 | $177 |
| Critical care, first 30-74 minutes | 41 | $20,852 | $197 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 125 | $19,605 | $66 |
| Return visit (30+ min) | 131 | $17,439 | $93 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 205 | $15,201 | $67 |
| Electrocardiogram (ecg) up to 30 days continuous with transmission of patient triggered events with review and report by health care professional | 12 | $9,980 | $768 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 41 | $9,451 | $231 |
| New patient visit (60+ min) | 43 | $7,850 | $183 |
| Short return visit (20+ min) | 72 | $6,172 | $70 |
| Short return visit | 90 | $4,461 | $44 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 161 | $3,062 | $16 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 24 | $2,183 | $84 |
| Programming of dual lead pacemaker system | 21 | $1,588 | $50 |
| Ultrasound of heart with probe in esophagus, with report | 13 | $1,396 | $100 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 155 | $1,284 | $8 |
| Anticoagulant management of patient taking warfarin | 12 | $1,178 | $11 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 32 | $649 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 32 | $436 | $14 |
| Ultrasound of heart blood flow, valves and chambers | 13 | $236 | $17 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 13 | $143 | $11 |
2018: 21 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 169 | $35,820 | $201 |
| Return visit (30+ min) | 168 | $21,614 | $83 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 111 | $20,364 | $170 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 94 | $17,123 | $63 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 61 | $14,119 | $228 |
| Long return visit (40+ min) | 106 | $13,986 | $122 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 179 | $12,455 | $64 |
| New patient visit (60+ min) | 47 | $8,195 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $6,992 | $91 |
| Short return visit (20+ min) | 46 | $3,298 | $66 |
| Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | 12 | $2,992 | $249 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 160 | $2,754 | $15 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 25 | $2,066 | $77 |
| Ultrasound of heart with probe in esophagus, with report | 18 | $2,012 | $96 |
| Short return visit | 44 | $1,902 | $40 |
| Programming of dual lead pacemaker system | 19 | $1,341 | $41 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 124 | $965 | $7 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 23 | $448 | $19 |
| Ultrasound of heart blood flow, valves and chambers | 19 | $356 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 23 | $301 | $13 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 20 | $246 | $11 |
2017: 20 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 143 | $33,254 | $217 |
| Return visit (30+ min) | 172 | $23,675 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 81 | $15,169 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 78 | $10,620 | $63 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 35 | $9,197 | $263 |
| Long return visit (40+ min) | 50 | $7,624 | $123 |
| Short return visit (20+ min) | 104 | $6,419 | $53 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 102 | $5,828 | $55 |
| New patient visit (60+ min) | 23 | $4,244 | $185 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $4,081 | $91 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 30 | $2,579 | $81 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 86 | $1,668 | $15 |
| Programming of dual lead pacemaker system | 19 | $1,573 | $48 |
| Ultrasound of heart with probe in esophagus, with report | 11 | $1,244 | $96 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 160 | $1,169 | $7 |
| Short return visit | 18 | $735 | $41 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 24 | $467 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 22 | $448 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 22 | $300 | $13 |
| Ultrasound of heart blood flow, valves and chambers | 11 | $194 | $16 |
2016: 25 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 161 | $36,411 | $218 |
| Return visit (30+ min) | 171 | $22,436 | $92 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 31 | $15,163 | $489 |
| Short return visit (20+ min) | 171 | $14,022 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $10,426 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 65 | $10,397 | $63 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 22 | $5,818 | $264 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 86 | $5,222 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $4,809 | $91 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 31 | $4,578 | $95 |
| Long return visit (40+ min) | 27 | $3,562 | $132 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 28 | $2,353 | $81 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 33 | $2,225 | $67 |
| New patient visit (45+ min) | 15 | $1,838 | $123 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 101 | $1,748 | $16 |
| Ultrasound of heart with probe in esophagus, with report | 16 | $1,645 | $103 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 65 | $1,326 | $18 |
| Programming of dual lead pacemaker system | 16 | $1,271 | $53 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 20 | $871 | None |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 14 | $625 | $30 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 61 | $501 | $7 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 14 | $275 | $20 |
| Ultrasound of heart blood flow, valves and chambers | 14 | $228 | $16 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 14 | $179 | $13 |
| Infusion, normal saline solution, 250 cc | 32 | $48 | None |
2015: 23 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 188 | $43,822 | $217 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 79 | $38,706 | $490 |
| New patient visit (45+ min) | 185 | $24,430 | $132 |
| Return visit (30+ min) | 148 | $20,497 | $91 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 79 | $19,479 | $124 |
| Short return visit (20+ min) | 134 | $12,541 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 74 | $12,171 | $64 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $10,007 | $176 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 67 | $3,947 | $56 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 59 | $3,865 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,928 | $91 |
| Programming of dual lead pacemaker system | 27 | $1,965 | $49 |
| Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 55 | $1,775 | None |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 23 | $1,765 | $71 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 109 | $1,749 | $15 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,487 | $106 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 60 | $1,255 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) | 28 | $866 | $31 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 13 | $566 | $31 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 28 | $555 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 11 | $217 | $20 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 11 | $142 | $13 |
| Infusion, normal saline solution, 250 cc | 28 | $10 | None |
2014: 20 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 63 | $29,620 | $470 |
| Return visit (30+ min) | 97 | $16,274 | $89 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 63 | $15,654 | $125 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $10,770 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 51 | $9,798 | $61 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 42 | $8,972 | $209 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $6,937 | $88 |
| New patient visit (45+ min) | 41 | $5,617 | $137 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 81 | $5,121 | $54 |
| Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270) | 51 | $4,667 | None |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 70 | $4,511 | $62 |
| Long return visit (40+ min) | 36 | $4,448 | $114 |
| Short return visit (20+ min) | 27 | $2,055 | $64 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 21 | $1,621 | $77 |
| Ultrasound of heart with probe in esophagus, with report | 16 | $1,516 | $89 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 43 | $699 | $15 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 17 | $322 | $18 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 12 | $226 | $19 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 12 | $148 | $12 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 16 | $49 | $3 |
2013: 17 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 37 | $18,108 | $489 |
| Return visit (30+ min) | 94 | $16,194 | $85 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 71 | $13,014 | $174 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 37 | $9,559 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 40 | $8,038 | $58 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $7,079 | $151 |
| New patient visit (45+ min) | 38 | $5,220 | $137 |
| Injection, adenosine for diagnostic use, 30 mg (not to be used to report any adenosine phosphate compounds; instead use a9270) | 26 | $4,330 | None |
| Short return visit (20+ min) | 49 | $4,163 | $61 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $3,078 | $85 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 54 | $3,010 | $49 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 38 | $2,481 | $64 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 24 | $1,859 | $74 |
| Long return visit (40+ min) | 14 | $1,544 | $110 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 29 | $740 | $18 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 42 | $675 | $15 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 28 | $241 | $7 |
Medicaid work
$270 in 2024
Medicaid paid $270 for 57 billed services this clinician did in 2024, up to 25 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 14 | $175 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 43 | $95 |
| 2024 | 57 | 2 | 25 | $270 |
| 2023 | 99 | 2 | 25 | $347 |
| 2022 | 60 | 1 | 19 | $182 |
| 2021 | 64 | 1 | 20 | $293 |
| 2020 | 46 | 1 | 14 | $141 |
| 2019 | 18 | 1 | 16 | $55 |
| 2018 | 30 | 1 | 16 | $161 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 87 | $284 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 12 | $63 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 60 | $182 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 64 | $293 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 46 | $141 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 18 | $55 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 30 | $161 |
Drugs they prescribed that Part D paid
$253,224
Pharmacies billed $253,224 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,376) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
1,188 generic and 188 brand-name prescriptions · $253,224 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 124 | $174,021 | $1,403 |
| Xarelto | 16 | $22,734 | $1,421 |
| Entresto | 15 | $20,952 | $1,397 |
| Amiodarone | 73 | $5,746 | $79 |
| Diltiazem 24hr Er (La) | 11 | $1,661 | $151 |
See all 28 drugs
| Eliquis | 124 | $174,021 | $1,403 |
| Xarelto | 16 | $22,734 | $1,421 |
| Entresto | 15 | $20,952 | $1,397 |
| Amiodarone | 73 | $5,746 | $79 |
| Diltiazem 24hr Er (La) | 11 | $1,661 | $151 |
| Atorvastatin | 120 | $1,578 | $13 |
| Losartan | 113 | $1,348 | $12 |
| Metoprolol | 122 | $1,071 | $9 |
| Diltiazem 24hr Er (Cd) | 19 | $911 | $48 |
| Carvedilol | 55 | $896 | $16 |
| Lisinopril | 77 | $773 | $10 |
| Metoprolol | 53 | $738 | $14 |
| Amlodipine Besylate | 91 | $653 | $7 |
| Bumetanide | 15 | $575 | $38 |
| Hydrochlorothiazide | 78 | $456 | $6 |
| Digoxin | 14 | $443 | $32 |
| Hydralazine | 24 | $416 | $17 |
| Rosuvastatin | 32 | $391 | $12 |
| Pravastatin | 24 | $311 | $13 |
| Furosemide | 33 | $300 | $9 |
| Olmesartan Medoxomil | 12 | $299 | $25 |
| Diltiazem 24hr Er | 14 | $263 | $19 |
| Verapamil Er | 11 | $258 | $23 |
| Potassium Chloride | 14 | $248 | $18 |
| Triamterene-Hydrochlorothiazid | 14 | $191 | $14 |
| Nitroglycerin | 12 | $153 | $13 |
| Losartan-Hydrochlorothiazide | 16 | $127 | $8 |
| Warfarin | 18 | $91 | $5 |
Year by year
| 2024 | 1,376 | 180 | 0% (0) | 14% | $253,224 |
| 2023 | 1,420 | 183 | 0% (0) | 12% | $247,945 |
| 2022 | 1,385 | 183 | 0% (0) | None | $208,891 |
| 2021 | 1,436 | 197 | 0% (0) | 13% | $238,721 |
| 2020 | 1,619 | 194 | 0% (0) | 15% | $265,846 |
| 2019 | 1,703 | 193 | 0% (0) | 12% | $211,749 |
| 2018 | 1,528 | 186 | 0% (0) | 11% | $163,630 |
| 2017 | 1,790 | 201 | 0% (0) | 12% | $146,069 |
| 2016 | 2,235 | 244 | 0% (0) | 19% | $206,398 |
| 2015 | 2,073 | 265 | 0% (0) | 20% | $191,934 |
| 2014 | 881 | 133 | 0% (0) | 21% | $71,747 |
| 2013 | 591 | 98 | 0% (0) | 22% | $44,525 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 26 drugs
| Eliquis | 108 | $149,630 | $1,385 |
| Xarelto | 22 | $33,871 | $1,540 |
| Entresto | 20 | $24,376 | $1,219 |
| Amiodarone | 64 | $6,505 | $102 |
| Atorvastatin | 132 | $2,284 | $17 |
| Nebivolol | 11 | $1,641 | $149 |
| Losartan | 78 | $1,502 | $19 |
| Metoprolol | 135 | $1,482 | $11 |
| Amlodipine Besylate | 121 | $1,394 | $12 |
| Lisinopril | 119 | $1,113 | $9 |
| Carvedilol | 58 | $1,016 | $18 |
| Metoprolol | 54 | $969 | $18 |
| Diltiazem 24hr Er (Cd) | 18 | $928 | $52 |
| Pravastatin | 37 | $660 | $18 |
| Hydralazine | 21 | $523 | $25 |
| Diltiazem | 14 | $501 | $36 |
| Olmesartan Medoxomil | 12 | $450 | $37 |
| Potassium Chloride | 15 | $374 | $25 |
| Losartan-Hydrochlorothiazide | 21 | $371 | $18 |
| Rosuvastatin | 17 | $316 | $19 |
| Hydrochlorothiazide | 74 | $295 | $4 |
| Verapamil Er | 11 | $245 | $22 |
| Atenolol | 11 | $214 | $19 |
| Warfarin | 24 | $203 | $8 |
| Furosemide | 25 | $185 | $7 |
| Nitroglycerin | 15 | $182 | $12 |
2022: 24 drugs
| Eliquis | 126 | $138,927 | $1,103 |
| Xarelto | 24 | $26,303 | $1,096 |
| Amiodarone | 71 | $5,227 | $74 |
| Atorvastatin | 120 | $2,106 | $18 |
| Metoprolol | 140 | $1,616 | $12 |
| Losartan | 75 | $1,563 | $21 |
| Amlodipine Besylate | 134 | $1,546 | $12 |
| Lisinopril | 111 | $1,177 | $11 |
| Metoprolol | 66 | $1,132 | $17 |
| Diltiazem 24hr Er (Cd) | 26 | $738 | $28 |
| Verapamil Er | 14 | $572 | $41 |
| Carvedilol | 31 | $520 | $17 |
| Pravastatin | 31 | $481 | $16 |
| Hydrochlorothiazide | 77 | $364 | $5 |
| Dilt-Xr | 15 | $343 | $23 |
| Olmesartan Medoxomil | 12 | $335 | $28 |
| Warfarin | 20 | $311 | $16 |
| Fenofibrate | 11 | $309 | $28 |
| Potassium Chloride | 13 | $239 | $18 |
| Losartan-Hydrochlorothiazide | 19 | $221 | $12 |
| Rosuvastatin | 19 | $215 | $11 |
| Atenolol | 15 | $197 | $13 |
| Clopidogrel | 11 | $154 | $14 |
| Furosemide | 29 | $79 | $3 |
2021: 25 drugs
| Eliquis | 120 | $144,750 | $1,206 |
| Xarelto | 19 | $23,810 | $1,253 |
| Amiodarone | 68 | $6,858 | $101 |
| Pacerone | 11 | $4,998 | $454 |
| Atorvastatin | 133 | $2,075 | $16 |
| Losartan | 74 | $1,961 | $27 |
| Metoprolol | 131 | $1,912 | $15 |
| Diltiazem 24hr Er (Cd) | 37 | $1,865 | $50 |
| Amlodipine Besylate | 120 | $1,704 | $14 |
| Lisinopril | 110 | $1,353 | $12 |
| Pravastatin | 36 | $1,050 | $29 |
| Verapamil Er | 19 | $889 | $47 |
| Metoprolol | 53 | $871 | $16 |
| Olmesartan Medoxomil | 15 | $831 | $55 |
| Carvedilol | 56 | $764 | $14 |
| Hydralazine | 23 | $719 | $31 |
| Rosuvastatin | 14 | $718 | $51 |
| Losartan-Hydrochlorothiazide | 17 | $613 | $36 |
| Hydrochlorothiazide | 77 | $459 | $6 |
| Warfarin | 19 | $393 | $21 |
| Potassium Chloride | 19 | $259 | $14 |
| Clopidogrel | 15 | $228 | $15 |
| Atenolol | 18 | $219 | $12 |
| Triamterene-Hydrochlorothiazid | 11 | $161 | $15 |
| Furosemide | 17 | $60 | $4 |
2020: 29 drugs
| Eliquis | 137 | $145,567 | $1,063 |
| Xarelto | 26 | $32,188 | $1,238 |
| Bystolic | 15 | $8,145 | $543 |
| Pacerone | 13 | $7,380 | $568 |
| Amiodarone | 64 | $6,785 | $106 |
| Atorvastatin | 161 | $2,902 | $18 |
| Diltiazem 24hr Er (Cd) | 50 | $2,709 | $54 |
| Amlodipine Besylate | 133 | $1,834 | $14 |
| Losartan-Hydrochlorothiazide | 15 | $1,590 | $106 |
| Metoprolol | 120 | $1,526 | $13 |
| Losartan | 76 | $1,457 | $19 |
| Lisinopril | 125 | $1,394 | $11 |
| Metoprolol | 64 | $1,387 | $22 |
| Rosuvastatin | 19 | $1,232 | $65 |
| Fenofibrate | 13 | $860 | $66 |
| Warfarin | 37 | $854 | $23 |
| Verapamil Er | 23 | $830 | $36 |
| Carvedilol | 57 | $775 | $14 |
| Olmesartan Medoxomil | 22 | $762 | $35 |
| Pravastatin | 32 | $761 | $24 |
| Hydralazine | 21 | $737 | $35 |
| Potassium Chloride | 17 | $640 | $38 |
| Hydrochlorothiazide | 74 | $511 | $7 |
| Fenofibrate | 12 | $470 | $39 |
| Clopidogrel | 25 | $451 | $18 |
| Triamterene-Hydrochlorothiazid | 16 | $239 | $15 |
| Furosemide | 26 | $209 | $8 |
| Atenolol | 14 | $160 | $11 |
| Simvastatin | 17 | $126 | $7 |
2019: 33 drugs
| Eliquis | 97 | $97,060 | $1,001 |
| Xarelto | 18 | $22,228 | $1,235 |
| Pradaxa | 11 | $10,990 | $999 |
| Bystolic | 19 | $9,429 | $496 |
| Multaq | 11 | $9,124 | $829 |
| Amiodarone | 65 | $8,726 | $134 |
| Brilinta | 13 | $6,496 | $500 |
| Diltiazem 24hr Er (Cd) | 55 | $3,596 | $65 |
| Atorvastatin | 163 | $3,175 | $19 |
| Metoprolol | 91 | $2,605 | $29 |
| Olmesartan Medoxomil | 34 | $2,231 | $66 |
| Metoprolol | 121 | $1,687 | $14 |
| Losartan | 90 | $1,477 | $16 |
| Fenofibrate | 16 | $1,331 | $83 |
| Potassium Chloride | 35 | $1,236 | $35 |
| Amlodipine Besylate | 108 | $1,205 | $11 |
| Verapamil Er | 31 | $1,149 | $37 |
| Lisinopril | 109 | $1,138 | $10 |
| Warfarin | 50 | $1,081 | $22 |
| Rosuvastatin | 16 | $1,014 | $63 |
| Pravastatin | 32 | $881 | $28 |
| Cartia Xt | 14 | $686 | $49 |
| Carvedilol | 46 | $668 | $15 |
| Clopidogrel | 30 | $559 | $19 |
| Hydrochlorothiazide | 86 | $553 | $6 |
| Hydralazine | 15 | $517 | $34 |
| Losartan-Hydrochlorothiazide | 27 | $472 | $17 |
| Dilt-Xr | 11 | $441 | $40 |
| Triamterene-Hydrochlorothiazid | 23 | $279 | $12 |
| Simvastatin | 23 | $267 | $12 |
| Furosemide | 18 | $232 | $13 |
| Nitroglycerin | 12 | $176 | $15 |
| Atenolol | 13 | $168 | $13 |
2018: 31 drugs
| Eliquis | 64 | $61,980 | $968 |
| Xarelto | 14 | $16,895 | $1,207 |
| Amiodarone | 56 | $12,376 | $221 |
| Bystolic | 18 | $8,729 | $485 |
| Multaq | 12 | $8,121 | $677 |
| Atorvastatin | 145 | $3,095 | $21 |
| Olmesartan Medoxomil | 33 | $2,915 | $88 |
| Metoprolol | 67 | $2,432 | $36 |
| Metoprolol | 134 | $1,889 | $14 |
| Flecainide Acetate | 16 | $1,835 | $115 |
| Fenofibrate | 14 | $1,436 | $103 |
| Diltiazem 24hr Er (Cd) | 37 | $1,305 | $35 |
| Warfarin | 73 | $1,290 | $18 |
| Pravastatin | 41 | $1,215 | $30 |
| Lisinopril | 107 | $1,163 | $11 |
| Potassium Chloride | 29 | $982 | $34 |
| Verapamil Er | 30 | $979 | $33 |
| Cartia Xt | 25 | $943 | $38 |
| Rosuvastatin | 18 | $912 | $51 |
| Amlodipine Besylate | 75 | $860 | $11 |
| Clopidogrel | 36 | $829 | $23 |
| Losartan | 55 | $718 | $13 |
| Carvedilol | 45 | $606 | $13 |
| Losartan-Hydrochlorothiazide | 34 | $474 | $14 |
| Simvastatin | 27 | $310 | $11 |
| Hydrochlorothiazide | 52 | $266 | $5 |
| Triamterene-Hydrochlorothiazid | 16 | $262 | $16 |
| Nitroglycerin | 11 | $220 | $20 |
| Jantoven | 12 | $161 | $13 |
| Atenolol | 15 | $159 | $11 |
| Furosemide | 12 | $141 | $12 |
2017: 33 drugs
| Eliquis | 27 | $24,810 | $919 |
| Pradaxa | 16 | $14,189 | $887 |
| Amiodarone | 41 | $8,536 | $208 |
| Olmesartan Medoxomil | 28 | $8,086 | $289 |
| Metoprolol | 90 | $3,850 | $43 |
| Olmesartan-Hydrochlorothiazide | 13 | $3,495 | $269 |
| Atorvastatin | 165 | $3,459 | $21 |
| Warfarin | 103 | $2,206 | $21 |
| Fenofibrate | 19 | $1,985 | $104 |
| Metoprolol | 139 | $1,808 | $13 |
| Diltiazem 24hr Er | 44 | $1,778 | $40 |
| Rosuvastatin | 22 | $1,771 | $81 |
| Potassium Chloride | 34 | $1,473 | $43 |
| Cartia Xt | 34 | $1,312 | $39 |
| Pravastatin | 46 | $1,311 | $29 |
| Digox | 12 | $1,207 | $101 |
| Verapamil Er | 33 | $1,148 | $35 |
| Lisinopril | 125 | $1,054 | $8 |
| Losartan-Hydrochlorothiazide | 51 | $920 | $18 |
| Clopidogrel | 55 | $899 | $16 |
| Carvedilol | 65 | $863 | $13 |
| Amlodipine Besylate | 77 | $734 | $10 |
| Isosorbide Mononitrate Er | 13 | $695 | $53 |
| Losartan | 58 | $652 | $11 |
| Valsartan-Hydrochlorothiazide | 14 | $622 | $44 |
| Sotalol | 14 | $557 | $40 |
| Simvastatin | 35 | $432 | $12 |
| Triamterene-Hydrochlorothiazid | 19 | $378 | $20 |
| Hydrochlorothiazide | 65 | $373 | $6 |
| Valsartan | 15 | $336 | $22 |
| Nitroglycerin | 15 | $278 | $19 |
| Atenolol | 14 | $207 | $15 |
| Furosemide | 24 | $180 | $7 |
2016: 43 drugs
| Benicar | 57 | $27,940 | $490 |
| Pradaxa | 31 | $21,166 | $683 |
| Crestor | 26 | $15,862 | $610 |
| Benicar Hct | 31 | $15,572 | $502 |
| Eliquis | 18 | $13,977 | $777 |
| Bystolic | 31 | $7,564 | $244 |
| Multaq | 12 | $6,642 | $553 |
| Amiodarone | 47 | $6,199 | $132 |
| Effient | 12 | $6,047 | $504 |
| Atorvastatin | 177 | $4,113 | $23 |
| Metoprolol | 99 | $3,488 | $35 |
| Diltiazem 24hr Er | 57 | $3,289 | $58 |
| Fenofibric Acid | 19 | $3,230 | $170 |
| Fenofibrate | 20 | $2,672 | $134 |
| Warfarin | 128 | $2,065 | $16 |
| Metoprolol | 140 | $1,773 | $13 |
| Pravastatin | 55 | $1,764 | $32 |
| Rosuvastatin | 14 | $1,697 | $121 |
| Potassium Chloride | 36 | $1,534 | $43 |
| Enoxaparin | 12 | $1,510 | $126 |
| Clopidogrel | 66 | $1,436 | $22 |
| Losartan | 108 | $1,423 | $13 |
| Lisinopril | 126 | $1,066 | $8 |
| Carvedilol | 67 | $1,061 | $16 |
| Amlodipine Besylate | 117 | $1,061 | $9 |
| Verapamil Er | 39 | $994 | $25 |
| Digox | 14 | $950 | $68 |
| Valsartan-Hydrochlorothiazide | 23 | $924 | $40 |
| Losartan-Hydrochlorothiazide | 49 | $883 | $18 |
| Sotalol | 26 | $767 | $29 |
| Digoxin | 14 | $740 | $53 |
| Valsartan | 14 | $643 | $46 |
| Isosorbide Mononitrate Er | 16 | $604 | $38 |
| Cartia Xt | 19 | $588 | $31 |
| Simvastatin | 54 | $575 | $11 |
| Hydrochlorothiazide | 62 | $445 | $7 |
| Nitrostat | 18 | $411 | $23 |
| Triamterene-Hydrochlorothiazid | 21 | $389 | $19 |
| Furosemide | 47 | $317 | $7 |
| Irbesartan | 11 | $302 | $27 |
| Spironolactone | 16 | $287 | $18 |
| Nitroglycerin Patch | 15 | $202 | $13 |
| Atenolol | 17 | $183 | $11 |
2015: 46 drugs
| Benicar | 53 | $19,636 | $370 |
| Crestor | 39 | $19,468 | $499 |
| Pradaxa | 19 | $13,435 | $707 |
| Benicar Hct | 32 | $11,795 | $369 |
| Bystolic | 31 | $9,588 | $309 |
| Ranexa | 20 | $9,526 | $476 |
| Enoxaparin | 23 | $7,187 | $312 |
| Effient | 11 | $6,639 | $604 |
| Amiodarone | 63 | $5,961 | $95 |
| Fenofibric Acid | 18 | $4,287 | $238 |
| Atorvastatin | 166 | $3,380 | $20 |
| Diltiazem 24hr Er | 44 | $2,892 | $66 |
| Metoprolol | 56 | $2,744 | $49 |
| Warfarin | 120 | $2,494 | $21 |
| Flecainide Acetate | 18 | $2,332 | $130 |
| Fenofibrate | 21 | $2,209 | $105 |
| Pravastatin | 35 | $1,739 | $50 |
| Losartan | 97 | $1,696 | $17 |
| Digox | 22 | $1,332 | $61 |
| Diltiazem Er | 25 | $1,248 | $50 |
| Potassium Chloride | 21 | $1,133 | $54 |
| Metoprolol | 117 | $1,124 | $10 |
| Sotalol | 36 | $1,056 | $29 |
| Cartia Xt | 27 | $1,054 | $39 |
| Valsartan | 15 | $1,038 | $69 |
| Amlodipine Besylate | 110 | $944 | $9 |
| Carvedilol | 68 | $940 | $14 |
| Valsartan-Hydrochlorothiazide | 18 | $784 | $44 |
| Lisinopril | 103 | $695 | $7 |
| Clopidogrel | 37 | $666 | $18 |
| Isosorbide Mononitrate Er | 16 | $509 | $32 |
| Taztia Xt | 12 | $488 | $41 |
| Hydrochlorothiazide | 94 | $485 | $5 |
| Verapamil Er | 33 | $449 | $14 |
| Losartan-Hydrochlorothiazide | 28 | $441 | $16 |
| Digoxin | 11 | $437 | $40 |
| Nitrostat | 15 | $431 | $29 |
| Irbesartan | 11 | $412 | $37 |
| Furosemide | 51 | $385 | $8 |
| Ramipril | 12 | $378 | $31 |
| Allopurinol | 15 | $319 | $21 |
| Simvastatin | 32 | $318 | $10 |
| Triamterene-Hydrochlorothiazid | 17 | $293 | $17 |
| Nitroglycerin Patch | 17 | $293 | $17 |
| Spironolactone | 13 | $266 | $20 |
| Atenolol | 11 | $109 | $10 |
2014: 23 drugs
| Benicar | 22 | $6,464 | $294 |
| Benicar Hct | 15 | $5,689 | $379 |
| Pradaxa | 13 | $4,984 | $383 |
| Bystolic | 17 | $4,733 | $278 |
| Diovan | 15 | $3,677 | $245 |
| Isosorbide Dinitrate | 11 | $1,579 | $144 |
| Fenofibrate | 14 | $1,474 | $105 |
| Diltiazem 24hr Er | 21 | $1,362 | $65 |
| Atorvastatin | 68 | $1,348 | $20 |
| Metoprolol | 12 | $903 | $75 |
| Losartan | 48 | $840 | $18 |
| Metoprolol | 80 | $829 | $10 |
| Clopidogrel | 20 | $763 | $38 |
| Warfarin | 31 | $636 | $21 |
| Diltiazem Er | 11 | $608 | $55 |
| Amlodipine Besylate | 47 | $580 | $12 |
| Carvedilol | 30 | $493 | $16 |
| Amiodarone | 19 | $472 | $25 |
| Isosorbide Mononitrate Er | 12 | $413 | $34 |
| Hydrochlorothiazide | 70 | $395 | $6 |
| Simvastatin | 22 | $222 | $10 |
| Lisinopril | 28 | $221 | $8 |
| Furosemide | 15 | $117 | $8 |
2013: 17 drugs
| Bystolic | 20 | $4,269 | $213 |
| Clopidogrel | 22 | $3,233 | $147 |
| Atorvastatin | 39 | $1,388 | $36 |
| Valsartan-Hydrochlorothiazide | 18 | $1,348 | $75 |
| Metoprolol | 14 | $729 | $52 |
| Isosorbide Mononitrate Er | 15 | $682 | $45 |
| Diltiazem 24hr Er | 11 | $544 | $49 |
| Losartan | 23 | $490 | $21 |
| Metoprolol | 42 | $474 | $11 |
| Hydrochlorothiazide | 63 | $419 | $7 |
| Simvastatin | 28 | $411 | $15 |
| Warfarin | 22 | $406 | $18 |
| Carvedilol | 24 | $383 | $16 |
| Amlodipine Besylate | 20 | $277 | $14 |
| Pantoprazole | 14 | $210 | $15 |
| Lisinopril | 19 | $195 | $10 |
| Furosemide | 11 | $119 | $11 |
Money from drug and device companies
$475 in 2025
| 2025 | 3 | 5 | None | $475 |
| 2024 | 2 | 2 | None | $178 |
| 2023 | 5 | 8 | None | $592 |
| 2022 | 2 | 2 | None | $274 |
| 2021 | 1 | 2 | None | $51 |
| 2020 | 1 | 1 | None | $21 |
| 2019 | 3 | 3 | None | $264 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biotronik | Amvia Edge | $252 | 2 payments
|
| Heartflow | Ffrct | $198 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $25 | 1 payment
|
See all 5 published payments
| E.R. Squibb & Sons L.L.C. | Meals · 2025-12-12 | Eliquis | $25 |
| Biotronik | Meals · 2025-09-18 | Amvia Edge | $167 |
| Biotronik | Meals · 2025-09-15 | Acticor 7 Vr-T Dx | $85 |
| Heartflow | Meals · 2025-03-19 | Ffrct | $167 |
| Heartflow | Meals · 2025-02-18 | Ffrct | $31 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $178
| Edwards Lifesciences | Edwards Sapien 3 Transcatheter Heart Valve (Thv) | $153 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $26 | 1 payment
|
2023: $592
| Bayer Healthcare Pharmaceuticals | Adempas | $238 | 3 payments
|
| Boston Scientific | Watchman Flx | $163 | 2 payments
|
| GE HealthCare | None | $156 | 1 payment
|
| Biotronik | Edora 8 Dr-T | $18 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $16 | 1 payment
|
2022: $274
| Biotronik | Rivacor 7 Dr-T | $159 | 1 payment
|
| Medtronic | Linq II | $115 | 1 payment
|
2021: $51
| Abbott Laboratories | Mitraclip System | $51 | 2 payments
|
2020: $21
| Janssen Pharmaceuticals | Xarelto | $21 | 1 payment
|
2019: $264
| Abiomed | Impella | $125 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Adempas | $125 | 1 payment
|
| Henry Schein | None | $14 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 0.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1124190954
- Licence
- CA A62620California A62620: Current · expires 2028-08-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 2516 Samaritan Dr, Suite H, San Jose, CA, 95124
- NPI first listed
- 2006-11-15
- NPI last updated
- 2014-04-01
This is when the NPI record was last certified, not a medical board exam.